Growth in innovative targeted therapies set to drive breast cancer therapeutics market in China, notes Frost & Sullivan.
Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in China. Currently, a larger number of breast cancer patients are pre-treated with taxanes as adjuvant chemotherapy is widely used and breast cancer is diagnosed earlier. In the future, the use of molecular targeted therapies as effective forms of cancer therapy will become more prevalent. However, drug manufacturers and the government need to work hand-in-hand in making these advanced therapies more accessible to the market.
New analysis from Frost & Sullivan (pharma.frost.com), Opportunities Assessment for Breast Cancer Therapeutics in China, finds that the total number of breast cancer patients in the country was 387,000 in 2009, and estimates this to increase by more than 20 percent within 2016. The study provides competitive structure, market analysis and future trends for the breast cancer drug therapies (cytotoxic, hormonal and targeted) in China.
If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Jasminder Kaur, Corporate Communications, at jkaur[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by email.
For now, molecular targeted therapies form a majority of the drugs in clinical development for breast cancer, followed by cytotoxic therapies and endocrine therapies. Biopharmaceutical companies are placing more emphasis on developing targeted breast cancer therapies that offer patients not only increased efficacy, but reduced side effects as well.
"Targeted therapeutics are the emerging trend in cancer therapies that rely on the biological differences between malignant and healthy cells to target the faulty genes or proteins that play a crucial role in breast cancer development," says Frost & Sullivan Research Analyst Carole Gaffud. "Combinations of these highly specific therapies with existing cytotoxic and hormonal therapies are rapidly becoming the standard of oncology care."
In China, there is a growing acceptance of targeted therapies for breast cancer. Breast cancer surgeons and medical oncologists regard targeted therapies as relatively safe treatments that are to be increasingly used in the future in China. Three targeted therapies in late-phase development include Certican/Afinitor (Novartis), Armala (GlaxoSmithKline), and Omnitarg (Roche).
"Although medical oncologists in China have shown high interest in the potential of new biological treatments, the high cost of biologicals is a major challenge and some specialists believe that their response does not justify the expense," notes Gaffud.
Due to the higher cost compared to cytotoxic and endocrine therapies, the use of targeted therapies in China is and would continue to be largely dependent on their price and availability on the National Reimbursement List. Those regimens believed to be the ‘optimal standard of care’, such as monoclonal antibodies and aromatase inhibitors, are not reimbursed in either early or advanced stage of the disease. And as most patients do not have the financial capability to afford these treatments; they are prescribed reimbursable products, which may have lower efficacy or present higher side effects.
"Overall, to thrive in this highly competitive market, drug developers must offer drugs that improve survival rates and the quality of life," concludes Gaffud. "At the same time, they could consider providing access to more drugs in pharmacies and hospitals at a lower cost."
Opportunities Assessment for Breast Cancer Therapeutics in China, is part of the Pharmaceutical & Biotechnology Growth Partnership Service program, which also includes research in the therapeutics market for Rheumatoid Arthritis, Hepatitis B, and Type 2 Diabetes, as well as the outlook for the pharmaceutical and biotechnology markets in various Asia Pacific countries. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents.
Opportunities Assessment for Breast Cancer Therapeutics in China